Digital Health C-Suite Series: Claritas Rx’s Stuart Kamin on proving the value of SaMD solutions

Csuite blog claritas

In the latest installment of our BrightInsight Digital Health C-Suite Series, we spoke with Claritas Rx Senior Vice President of Corporate Strategy and Business, Stuart Kamin, about how patient-level data integration and analytics can help measure digital’s actual impact on patients, and how to increase confidence in digital health solutions. Watch the interview or read on for a recap.

Improving the patient experience

Claritas Rx is dedicated to using data and analytics to help patients on specialty drugs have a better experience with their therapies.

“Our platform integrates a broad array of commercial patient-level data and uses domain-driven analytics and machine learning to mine that data and identify rich, actionable insights about the patient experience and brand performance on a daily basis.”

The company has a deep bench of life science expertise. “We understand not only the questions that biotech companies have, but analytically how to answer them. The data that are the backbone of our platform really come alive once a patient is prescribed one of these treatments.”

Although there’s a lot of focus in digital health on expanding access to underserved patient pools, on helping the sales and marketing teams achieve commercial objectives, there's also a large unmet need around data and analysis after the patient is prescribed.

For Claritas Rx, “helping make sure that every patient that is appropriate for treatment gets on treatment, and stays on treatment as is appropriate,” is as important as helping achieve commercial targets.

“We have a suite of solutions that's quite differentiated, not only by creating visibility into those patients who are blocked from treatment and helping them to get on through creating new knowledge, but actually having tools and partnerships with digital solutions like BrightInsight to actualize that insight, to enable interventions at the right time, to help patients in the real world.”

Working with BrightInsight to overcome barriers

“We are really excited about collaborations that we're doing, with BrightInsight and other digital tools.” It’s well documented that barriers to access and treatment are devastating for patients and cost the U.S. healthcare system billions of dollars a year. Actors across the system know this, and they have very sophisticated programs for supporting patients, for helping them transcend those barriers, with many different components, from provider services to affordability.

Digital is playing an increasingly important role in that. “What we find to be a big barrier to more adoption of digital solutions is simply the ability to prove that they work, to prove their effectiveness in the real world. If you could show in the data that a digital tool really moved the needle, really helped to get more patients on a drug or keep them on a drug, it would help justify further adoption of these tools, and integration into these larger ecosystems.”

The challenge is that a lot of that data has been very limited, making it difficult to take a scientific approach to integrating digital tools. “If there's no data, there's no ability to figure out what actually works.” Claritas Rx created a unique dataset that sheds new light on components of the patient journey and is using it to benchmark what “good” looks like in terms of market access and patient services teams.

“This is a very natural way for us to be collaborating with BrightInsight, for example, to show how they impact patients relative to controls, and to prove quantitatively that these digital tools can have a very material impact on patients.”

Measuring the ROI in digital health

“Ultimately, it does come down to the ability to show it in the numbers. It has a lot to do with the sort of data that you're looking at, how you create a robust, essentially synthetic control for a tool like the BrightInsight Platform.”

The Claritas Rx solution reveals, for particular patient populations over a particular period of time, material improvement in outcomes such as fill rate, speed to therapy and adherence. “That does lower the barrier to what you have to believe to adopt one of these tools. And I think it will only increase in the future, when the array of available tools and their ability to impact the patient experience will just grow, and people will want to take a more quantitative approach to optimizing their patient services programs.”

Find all interviews from our Digital Health C-Suite Series on our YouTube Channel.

Back to Blog